CLOs on the Move

Optinose

www.optinose.com

 
We are a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists. Our first commercial product, XHANCE® (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing our proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and, if approved, chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). In September 2017, the U.S. Food and Drug Administration (FDA) approved XHANCE for the treatment of nasal polyps in patients 18 years of age or ...
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.optinose.com
  • 1020 Stony Hill Road Suite 300
    Yardley, PA USA 19067
  • Phone: 267.364.3500

Executives

Name Title Contact Details

Similar Companies

Nuvo Research

Nuvo Research Inc. is a Mississauga, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Transtracheal Systems Inc

Transtracheal Systems Inc is a Englewood, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Soliton

Soliton has developed breakthrough science for tattoo removal using Rapid Acoustic Pulse (RAP) technology, which when combined with existing laser technology can rapidly accelerate tattoo removal.

BioMed Supply

BioMed Supply, Inc. is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Accumulus

Accumulus Synergy is a global, non-profit organization that is developing a transformative data exchange platform that aims to enable enhanced collaboration and efficiency between life sciences organizations and global health authorities, while also affording users the ability to extract dynamic, data-driven insights from knowledge management. Sponsored by leading biopharmaceutical companies, Accumulus Synergy was formed in 2020 to create innovative solutions that can reduce regulatory review times and transform global data exchange. The non-profit company is creating a first-of-its-kind cloud-based platform between the biopharmaceutical industry and health authorities worldwide. The single-platform approach aims to improve speed, transparencies and efficiencies in the regulatory process by leveraging advanced technology and tools for data exchange. This will help reduce the cost of innovation and ultimately bring patients safe and effective medicines faster.